| European Case Law Identifier: | ECLI:EP:BA:2017:T078216.20170718 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 18 July 2017 | ||||||||
| Case number: | T 0782/16 | ||||||||
| Application number: | 10179085.5 | ||||||||
| IPC class: | A61K 9/70 A61K 31/27 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Transdermal therapeutic system for the administration of rivastigmine | ||||||||
| Applicant name: | Novartis AG Novartis Pharma GmbH LTS LOHMANN Therapie-Systeme AG |
||||||||
| Opponent name: | Easypharm GmbH & Co KG Acino Pharma AG Alvogen IPCo S.à r.l STADA Arzneimittel AG neuraxpharm Arzneimittel GmbH SK Chemicals Co., Ltd. Generics [UK] Limited Actavis Group PTC ehf Genericon Pharma Gesellschaft m.b.H. PENTAFARMA, Sociedade Técnico-Medicinal, SA TECNIMEDE ESPAÃA Industria Farmacéutica, S.A. Dr. Reddy's Laboratories (UK) Limited/ betapharm Arzneimittel GmbH Biogaran |
||||||||
| Board: | 3.3.07 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Divisional application - added subject-matter (yes) Amendments - added subject-matter (yes) Reimbursment of appeal fee (no) |
||||||||
| Catchwords: |
Reasons, points 4.1.1 to 4.1.3 |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t160782eu1.html
Date retrieved: 17 May 2021